X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs VENUS REMEDIES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS VENUS REMEDIES IPCA LABS/
VENUS REMEDIES
 
P/E (TTM) x 30.6 -1.4 - View Chart
P/BV x 4.5 0.1 4,404.5% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   VENUS REMEDIES
EQUITY SHARE DATA
    IPCA LABS
Mar-18
VENUS REMEDIES
Mar-18
IPCA LABS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs695126 552.3%   
Low Rs40061 654.7%   
Sales per share (Unadj.) Rs260.2301.8 86.2%  
Earnings per share (Unadj.) Rs19.0-24.9 -76.3%  
Cash flow per share (Unadj.) Rs33.12.5 1,299.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.0293.3 72.6%  
Shares outstanding (eoy) m126.2012.34 1,022.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.10.3 679.4%   
Avg P/E ratio x28.9-3.8 -767.9%  
P/CF ratio (eoy) x16.636.7 45.1%  
Price / Book Value ratio x2.60.3 806.4%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,1201,154 5,990.7%   
No. of employees `00013.30.9 1,432.9%   
Total wages/salary Rs m7,359393 1,872.0%   
Avg. sales/employee Rs Th2,477.44,026.1 61.5%   
Avg. wages/employee Rs Th555.2425.0 130.6%   
Avg. net profit/employee Rs Th180.6-331.8 -54.4%   
INCOME DATA
Net Sales Rs m32,8363,724 881.7%  
Other income Rs m41823 1,857.8%   
Total revenues Rs m33,2543,747 887.6%   
Gross profit Rs m4,505395 1,141.0%  
Depreciation Rs m1,777338 525.4%   
Interest Rs m240354 67.8%   
Profit before tax Rs m2,905-275 -1,055.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m51132 1,617.4%   
Profit after tax Rs m2,394-307 -780.1%  
Gross profit margin %13.710.6 129.4%  
Effective tax rate %17.6-11.5 -153.3%   
Net profit margin %7.3-8.2 -88.5%  
BALANCE SHEET DATA
Current assets Rs m19,4552,638 737.6%   
Current liabilities Rs m10,0762,305 437.2%   
Net working cap to sales %28.68.9 319.4%  
Current ratio x1.91.1 168.7%  
Inventory Days Days98135 72.3%  
Debtors Days Days6746 144.5%  
Net fixed assets Rs m20,2604,871 415.9%   
Share capital Rs m252123 204.5%   
"Free" reserves Rs m26,6333,496 761.9%   
Net worth Rs m26,8863,619 742.9%   
Long term debt Rs m2,3401,374 170.3%   
Total assets Rs m41,1737,509 548.4%  
Interest coverage x13.10.2 5,873.0%   
Debt to equity ratio x0.10.4 22.9%  
Sales to assets ratio x0.80.5 160.8%   
Return on assets %6.40.6 1,013.5%  
Return on equity %8.9-8.5 -105.0%  
Return on capital %10.81.6 680.3%  
Exports to sales %47.60-   
Imports to sales %14.913.9 107.2%   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884517 945.4%   
Fx inflow Rs m15,6420-   
Fx outflow Rs m4,884517 945.5%   
Net fx Rs m10,759-517 -2,083.0%   
CASH FLOW
From Operations Rs m3,411514 663.2%  
From Investments Rs m-1,354-123 1,099.9%  
From Financial Activity Rs m-1,304-387 336.9%  
Net Cashflow Rs m7534 17,933.3%  

Share Holding

Indian Promoters % 45.9 32.9 139.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.2 6,333.3%  
FIIs % 25.3 0.6 4,362.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 66.4 26.2%  
Shareholders   36,892 20,121 183.4%  
Pledged promoter(s) holding % 2.1 36.4 5.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 495 Points, Jet Airways in Focus and Other Top Stocks in Action Today(Pre-Open)

On Monday, share markets in India opened on a negative note and ended the day deep in red after a volatile day of trading.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Apr 22, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - STERLING BIOTECH COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS